5-alpha-reductase inhibitors

5-α-re·duc·tase in·hib·i·tors

(rĕ-dŭk'tās in-hib'i-tŏrz)
Drugs that inhibit the action of 5α-reductase, resulting in lower levels of prostatic dihydrotestosterone, produced by the enzyme from testosterone as the primary androgen in the prostate.
References in periodicals archive ?
Nephrology and urology segment is further divided into diuretic drugs, anti-hypertensive agents, phosphate binders, anti-cholinergic agents and 5-alpha-reductase inhibitors.
4] The mainstay of medical treatments includes alpha-blockers, 5-alpha-reductase inhibitors (5-ARIs), or a combination of the two.
First-line therapies indude alpha-1 adrenergic receptor antagonists (alpha-blockers) and 5-alpha-reductase inhibitors (5-AR1s).
Exclusion criteria also included: consumption of food rich in soy isoflavonoids, dietary supplements of any kind, medication with possible effects on prostate health such as antibiotics, anti-inflammatory drugs, alpha-1 -adrenoreceptor antagonist and 5-alpha-reductase inhibitors.
Cancer chemopreventive approaches may include 5-alpha-reductase inhibitors, histone deacetylase inhibitors, antioxidans, non-steroidal anti-inflammatory drugs, cholesterol-lowering statins, vitamin D analogues.
FDA-approved conventional medications used to treat BPH are of two categories, alpha-antagonists and 5-alpha-reductase inhibitors.
The new chapter on non-neurogenic lower urinary tract symptoms (LUTS), including nocturia, incorporates information on a variety of LUTS treatment options including alpha-blockers and 5-alpha-reductase inhibitors.
Medications called 5-alpha-reductase inhibitors (Proscar, for example) help shrink the prostate.
Previous treatment with 5-alpha-reductase inhibitors was not allowed and alpha-blockers were discontinued at least 14 days prior to study.
195 (9%) took the medication 5-alpha-reductase inhibitors (ARIs).
In 2011, the FDA mandated labeling changes for all 5-alpha-reductase inhibitors, stating that the drugs are not approved for use as preventives and they may raise the risk of high-grade prostate cancers.
The continuing Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial may help define a role for the 5-alpha-reductase inhibitors in cancer chemoprevention.

Full browser ?